Cargando…

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours

Patients treated with tamoxifen (TAM) for primary breast cancer often manifest de novo or acquired resistance, possibly through changes in drug metabolism. Using solid-phase extraction methods and reversed-phase high-performance liquid chromatography separations, levels of TAM and metabolites 4-hydr...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacCallum, J, Cummings, J, Dixon, J M, Miller, W R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374506/ https://www.ncbi.nlm.nih.gov/pubmed/10817496 http://dx.doi.org/10.1054/bjoc.2000.1120

Ejemplares similares

Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy - reply: Reply to the letter from Benson and Colletta
por: MacCallum, J, et al.
Publicado: (1997)

Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.
por: MacCallum, J., et al.
Publicado: (1996)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
por: Milano, G., et al.
Publicado: (1987)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
por: Woo, Hye In, et al.
Publicado: (2017)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
por: Parisot, J P, et al.
Publicado: (1999)

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
por: Khalaj, Zahra, et al.
Publicado: (2019)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas
por: Freihoff, D, et al.
Publicado: (1999)

Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells
por: Al-Nabulsi, I, et al.
Publicado: (1999)

Expression of transforming growth factor beta mRNA isoforms in human breast cancer.
por: MacCallum, J., et al.
Publicado: (1994)

Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
por: Trinconi, Cristiana T., et al.
Publicado: (2018)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women
por: Daidone, M G, et al.
Publicado: (2000)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
por: Helland, Thomas, et al.
Publicado: (2017)

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
por: Dixon, A. R., et al.
Publicado: (1992)

Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model
por: Xiao, Z, et al.
Publicado: (1999)

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010)

Reply to letter from Mr Benson and Professor Baum
por: MacCallum, J., et al.
Publicado: (1994)

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
por: Clarke, R. B., et al.
Publicado: (1993)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000)

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer
por: Rehnmark, Stefan, et al.
Publicado: (2022)

Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones
por: Dankers, Anita C. A., et al.
Publicado: (2012)

The Melanin-concentrating Hormone System in Human, Rodent and Avian Brain
por: Bencze, János, et al.
Publicado: (2018)

Generation of brain tumours in mice by Cre-mediated recombination of neural progenitors in situ with the tamoxifen metabolite endoxifen
por: Benedykcinska, Anna, et al.
Publicado: (2016)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer
por: Mo, Zhiqiang, et al.
Publicado: (2013)

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ
por: Bijker, N, et al.
Publicado: (2001)

Reproducibility of microvessel counts in breast cancer specimens
por: Marson, L P, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_0to3vdi7rgt6e86oq6qdna3uej